Gordon Saul

Gordon Saul is a prominent figure in the healthcare and medical technology sectors, currently serving as a Board Member at Applaud Medical, Inc. and as the Executive Director of the Stanford Byers Center for Biodesign. His extensive background combines experience in healthcare innovation, venture capital, and education.

Education and Early Career

Saul earned his AB in Engineering Sciences (Chemistry) from Dartmouth College in 1984 and later obtained an MBA from Stanford University in 1991. His early career included roles at the Boston Consulting Group and in finance, as well as working abroad in Japan, where he developed proficiency in Japanese.24

Professional Journey

Before joining Stanford Biodesign, Saul played a significant role in the success of various health technology companies. He was instrumental in guiding a novel drug delivery company through its early financing stages to a successful public offering. Following this achievement, he spent 12 years as an executive-in-residence at InterWest Partners, where he took on leadership roles in several innovative technology firms.23

At Stanford Biodesign, where he has been since 2013, Saul focuses on fostering healthcare innovation through education and collaboration. He teaches courses on innovation implementation and manages grant programs that support translational projects aimed at commercial development.24

Contributions to Applaud Medical

As a board member at Applaud Medical, Saul contributes to the strategic direction of the company, which is developing the BRIO System, an acoustic cavitation lithotripsy system designed for treating kidney stones with minimal invasiveness.1 His expertise in medical technology and innovation positions him as a valuable asset to the company's mission.

Gordon Saul's multifaceted career reflects his commitment to advancing healthcare through innovation and education, making significant contributions to both academic environments and industry practices.